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Background: The aim of this study was to evaluate the relation of some ultrasound morphological parameters to
biological characteristics in breast carcinoma.
Methods: Ultrasound data from 315 breast masses were collected. We analyzed the ultrasound features of the
tumors according to the ACR BI-RADS®-US classification system stratified by hormone receptor status, HER2 status,
histology grade, tumor type (ductal versus lobular), triple-negativity, breast density, tumor size, lymph node involvement
and patient’s age.
Results: We found a variety of ultrasound features that varied between the groups. Invasive lobular tumors were more
likely to have an angulated margin (39% versus 22%, p = 0.040) and less likely to show posterior acoustic enhancement
(3% versus 16%, p = 0.023) compared to invasive ductal carcinoma. G3 tumors were linked to a higher chance of
posterior acoustic enhancement and less shadowing and the margin of G3 tumors was more often described as
lobulated or microlobulated compared to G1/G2 tumors (67% versus 46%, p = 0.001). Tumors with an over-expression
of HER2 exhibited a higher rate of architectural distortions in the surrounding tissue, but there were no differences
regarding the other features. Hormone receptor negative tumors were more likely to exhibit a lobulated or microlobulated
margin (67% versus 50%, p = 0.037) and less likely to have an echogenic halo (39% versus 64%, p = 0.001). Furthermore,
the posterior acoustic feature was more often described as enhancement (33% versus 13%, p = 0.001) and less often as
shadowing (20% versus 47%, p < 0.001) compared to hormone receptor positive tumors.
Conclusion: Depending on their biological and clinical profile, breast cancers are more or less likely to exhibit the
typical criteria for malignancy in ultrasound. Moreover, certain types of breast cancer tend to possess criteria that are
usually associated with benign masses. False-negative diagnosis may result in serious consequences for the patient. For
the sonographer it is essential to be well aware of potential variations in the ultrasound morphology of breast tumors,
as described in this paper.
Keywords: Breast ultrasound, Cancer detection, Ultrasound features, Tumor biologyBackground
Breast cancer is not a single disease. A great diversity con-
cerning histopathology, immunohistochemistry, genetics
and clinical presentation must be considered. The know-
ledge about fundamental tumor characteristics is gradually
evolving and the elementary pathological division of* Correspondence: s@wojcinski.de
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reproduction in any medium, provided the orbreast tumors into ductal, lobular and other types be-
comes more and more complex.
The Nottingham modification of the Bloom-Richardson
grading system, also known as Nottingham Histology
Grade (NHG), provides a mean for the description of
tumor biology [1,2]. Low-grade tumors (i.e. G1) imply a
better prognosis than high-grade tumors (i.e. G3) [3]. In
1960, Elwood Jensen first described the estrogen receptor
(ER) and provided the basis for a more profound under-
standing of breast cancer [4]. Over-expression of the hu-
man epidermal growth factor receptor 2 (HER2) in breastal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prognostic factor and a predictive factor [5]. HER2-
overexpressed tumors are known to progress rapidly and
have a short interval to distant metastases [6]. On the
other hand, the HER2-receptor is the target for an effect-
ive therapy, the antibody-based drug Trastuzumab [7].
Nowadays, a much deeper insight into the molecular
backgrounds of breast cancer exists. Just recently, gene
expression profiles demonstrated that there are at least
five different intrinsic subtypes of breast cancer (luminal
A, luminal B, claudin-low, HER2-enriched, and basal-
like) [8-10]. The progression of a tumor, the time and
the pattern of distant metastasis and finally the progno-
sis of the disease are all highly driven by factors that are
intrinsic to the distinct tumor type. The tumor biology
may also have an influence on the presentation of malig-
nant lesions in breast imaging.
Breast ultrasound, alone or as an adjunct to mammog-
raphy, is a precise imaging modality with high sensitivity
and specificity in the evaluation of breast lesions
[11-13]. The standardized American College of Radi-
ology BI-RADS®-US-classification for breast tumors pro-
vides a variety of categories with predefined terminology
to describe the sonographic appearance of a breast
lesion [14].
The accurate prediction of the malignant or benign
character of a lesion plays a crucial role for the patient,
but false-negative and false-positive results may occur.
Breast cancer may simulate a benign lesion and vice
versa, as there is some overlap in the sonographic fea-
tures of malignant and benign tumors. Triple-negative
breast cancer (TNBC), for example, exhibits significantly
different features in ultrasound than non-TNBC [15].
False-positive diagnosis may result in an elevated rate of
unnecessary biopsies. The false-negative diagnosis of
breast cancers may result in delayed diagnosis and a
worse outcome for the patient. Therefore, knowledge
about the classic presentation of breast cancer in ultra-
sound and possible variations in distinct subtypes of
breast cancer is crucial for the examiner to determine
the malignant or benign character of a lesion precisely.
We scrutinized whether the sonomorphology of malig-
nant breast tumors is correlated to biological features of
the tumor.
Methods
General design and image database
Our study was carried out at the Breast Cancer Center
of Franziskus Hospital in Bielefeld, Germany. Patients
with a sonographically visible lesion that proved to be
malignant were regarded as being suitable for our study.
Patients with recurrent breast cancer, inflammatory
breast cancer and tumors involving the skin were
excluded.From the hospital database, 435 consecutive breast
cancer patients who attended our institution between
October 2008 and January 2011 were retrospectively col-
lected. Digitally recorded ultrasound images were avail-
able for 383 of the 435 breast cancer patients. Of these
patients, 62 were excluded as they presented non-
invasive breast cancer (ductal carcinoma in situ, DCIS)
and 6 were excluded as data concerning medical history,
receptor status, tumor stage, and/or treatment were
missing. Following their exclusion, we created a database
containing clinical data and digital ultrasound images
from 315 patients.
As the ultrasound images had been obtained using a
standard of care clinical protocol within the routine
practice of our breast cancer center, our institutional
ethics committee did not require additional approval for
this non-interventional retrospective study design. The
underlying ultrasound examinations were performed by
one of four senior consultants in breast diagnostics, all
of whom had at least 5-years’ experience in breast ultra-
sound. The examiners applied two high-end ultrasound
scanners: The Siemens ACUSON S2000™ ultrasound
system (Siemens Medical Solutions, Inc, Mountain View,
CA, USA) equipped with the 18 L6 HD linear trans-
ducer (5.5–18 MHz, 5.6 cm) and the Hitachi HI VISION
900 ultrasound system (Hitachi Medical Corporation,
Inc, Tokyo, Japan) equipped with the EUP L54M linear
transducer (6–13 MHz, 5.0 cm). As standard of care, all
patients received bilateral whole breast ultrasound and
sonographic evaluation of the axillary regions. According
to the diagnostic standards, the B-mode pictures of the
tumor were documented in two planes (sagittal and
horizontal).
Image analysis
The anonymized image database was analyzed by the
author SW, a DEGUM (German Society for Ultrasound
in Medicine) level II certified senior consultant in
gynecology with 7 years’ experience in breast ultrasound
[16]. SW was blinded to the patients’ characteristics and
histological results and evaluated the 315 lesions accord-
ing to the ACR BI-RADS®-US classification system and
the recommendations of the DEGUM [14,17]:
 Shape: Oval, round or irregular;
 Orientation: Horizontal (i.e. parallel), indifferent
(including round), vertical or not determinable;
 Margin: Circumscribed or not circumscribed (with
any of the following)
 Indistinct margin: Yes or no;
 Lobulated margin: Yes or no;
 Microlobulated margin: Yes or no;
 Angulated: Yes or no;
 Spiculated: Yes or no;
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interface;
 Echo pattern: Anechoic, hypoechoic, isoechoic,
hyperechoic or complex;
 Posterior acoustic features: Shadowing, no posterior
acoustic features, enhancement or combined
pattern;
 Architectural distortion of the surrounding tissue:
Yes or no;
 Changes in Cooper’s ligaments: Disrupted or
displaced.
Then, the results from the systematic image interpret-
ation were merged with the clinical data of the patients.
Comparisons of baseline demographic data, tumor char-
acteristics, and ultrasound features were made between
the following groups:
 Breast density: ACR 1 and 2 versus ACR 3 and 4;
 Tumor type: invasive ductal carcinoma (IDC) versus
invasive lobular carcinoma (ILC);
 Tumor grade: G1 and G2 versus G3 ; G1 versus G2
and G3;
 HER2 status: negative versus positive;
 Hormone receptor (HR) status: negative versus
positive;
 Lymph node involvement: N0 versus N+;
 Tumor size: T1 versus T2, T3 and T4;
 Age: <40 years versus >40 years; <50 years versus
>50 years; <60 years versus >60 years.
 Triple-negativity: TNBC versus non-TNBC.
Concerning the tumor type, most of the cases revealed
to be IDC or ILC (84.7%). Therefore, other rare types (e.g.
mucinous, medullary, tubular, mixed forms) were ex-
cluded from this distinct analysis. Vascularity and elasticity
were not analyzed, as there were not enough images in
our database that displayed these features.
Pathology and immunohistochemistry
All pathological and immunohistochemical examinations
concerning the workup of the tumor tissue were rou-
tinely performed by the pathology lab of our breast can-
cer center. The laboratory regularly participates in the
recommended round robin tests for quality assurance.
ER, PR, and HER2 were determined by immunohisto-
chemistry. For ER and PR, the cutoff level for receptor
positivity was defined as ≥1%. HER2 positivity was de-
fined as strong complete membrane staining of ≥ 10%of
the tumor cells (i.e. Score 3+). An additional fluorescent
in situ hybridization (FISH) assay was performed to de-
tect possible gene amplification and HER2 positivity for
Score 2+. Score 1+ and Score 0 were defined as HER2-
negative.Statistical analysis
We collected our data using Microsoft® Office Excel®
2007 (Microsoft Corporation). The author NS per-
formed the statistical analysis and the results were vali-
dated by the author SW. The analysis was performed
using MedCalc® 11.6 statistical software (MedCalc
Software bvba, Belgium). The Student’s t-test was used for
numerical data and comparison of means. Ultrasono-
graphic features of TNBC and non-TNBC were compared
using Fisher’s exact test for univariate distributions and
Yates’ chi-square test for multivariate distributions of cat-
egorical data. When Yates’ chi-square test was found to be
significant, pairwise comparisons were performed using
Fisher’s exact test. Statistical significance was assumed at
p < 0.05 for all tests.Results
Clinical examples for different tumor types are given in
Figures 1, 2, 3, 4 and 5. The results concerning the sono-
graphic presentation of the tumors are summarized in
Figure 6. The clinical aspects of the tumors are summa-
rized Figure 7. Key aspects are described in the following
paragraphs and will be discussed in the next section.Breast density
The pre-existing breast density had little effect on the
sonomorphology of the tumors. Nevertheless, in dense
breast tissue (according to the American College of
Radiology, ACR 3 and 4) tumors were more likely to
have a horizontal orientation than in less dense breast
tissue (53% versus 39%, p = 0.04).Tumor type
IDC and ILC cancer showed two different ultrasound fea-
tures. ILC was more likely to have an angulated margin
(39% versus 22%, p = 0.040) and less likely to show poster-
ior acoustic enhancement (3% versus 16%, p = 0.023).Tumor grade
Compared to moderately and well differentiated tumors,
poorly differentiated tumors (i.e. G3) were linked to a
higher chance of posterior acoustic enhancement and
less shadowing (31% versus 9%, p < 0.001; 25% versus
49%, p < 0.001). Furthermore, the margin of G3 tumors
was more often described as lobulated or microlobulated
compared to G1/G2 tumors (67% versus 46%, p = 0.001).HER2 status
We found only one ultrasound feature that was associated
with HER2-positivity. Tumors with an over-expression of
HER2 exhibited a higher rate of architectural distortions
in the surrounding tissue.
Figure 1 Invasive ductal carcinoma in a 72 year old patient (HR positive, Her2 negative, G2). The tumor exhibits typical ultrasound criteria
for malignancy (irregular, hypoechoic mass with an indistinct, spiculated margin, an echogenic halo, posterior shadowing and architectural
distortion of the surrounding tissue).
Figure 2 Invasive lobular carcinoma in a 75 year old patient (HR positive, Her2 negative, G2). The tumor appears as a hypoechoic architectural
distortion with an indistinct, angulated margin.
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Figure 3 Her2/neu-positive HR-positive tumor in a 57 year old patient (G3, invasive ductal). The tumor presents as a hypoechoic mass
with relevant architectural distortion of the surrounding tissue.
Figure 4 Her2/neu-positive HR-negative tumor in a 47 year old patient (G3, invasive ductal). The tumor presents as a bizarre, hypoechoic
mass with architectural distortion of the surrounding tissue and a widely lobulated or microlobulated margin, but no echoic halo.
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Figure 5 Triple-negative breast cancer in a 52 year old patient (G3, invasive ductal). The tumor appears as a lobulated, hypoechoic mass.
The ligaments are displaced rather than disrupted.
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The HR status had a relevant impact on the sonomor-
phology. Tumors that neither expressed estrogen nor
progesterone receptors were more likely to exhibit a
lobulated or microlobulated margin (67% versus 50%,
p = 0.037) and less likely to have an echogenic halo (39%
versus 64%, p = 0.001). Furthermore, the posterior acoustic
feature was more often described as enhancement (33%
versus 13%, p = 0.001) and less often as shadowing (20%
versus 47%, p < 0.001) compared to HR positive tumors.
Finally, displacement of the Cooper’s ligaments (instead of
disruption) was more often found in ER/PR negative
tumors (39% versus 14%, p = 0.002).
Tumor size
Several ultrasound features were dependent on the
tumor size. Small tumors (i.e. T1) were more likely to
have a round or oval shape (33% versus 21%, p = 0.026)
and less likely to exhibit a lobulated or angulated/spicu-
lated margin (15% versus 29%, p = 0.002; 29% versus
41%, p = 0.040). Furthermore, small tumors showed less
architectural distortions (71% versus 90%, p < 0.001).
Age
Patients’ age had a relevant influence on the sonomor-
phology of the tumors. Depending on the cut-off for the
age groups, we obtained the following results: In youn-
ger patients, the tumors were more likely to present with
a round or oval shape and exhibit a lobulated or micro-
lobulated margin. On the other hand, an angulatedmargin was less often observed. In the group of older
patients, an echogenic halo was described more fre-
quently. In young patients, a posterior acoustic enhance-
ment was more often seen and shadowing was less
often. Furthermore, architectural distortions were less
frequently described in young patients and the Cooper’s
ligaments were more often described as displaced rather
than disrupted.
Triple-negative breast cancer
As described elsewhere, triple negativity of breast cancer
has a relevant effect on the sonomorphology. The mar-
gin of TNBC was more frequently described as lobulated
and/or microlobulated (76% versus 50%, p = 0.005) and
the echogenic halo was observed significantly less often
compared to non-TNBC (39% versus 63%, p = 0.014).
Cooper’s ligaments were displaced rather than disrupted
in TNBC in comparison to non-TNBC (42% versus 14%,
p = 0.003). Posterior acoustic enhancement was more
frequent in TNBC (36% versus 13%, p = 0.001) and pos-
terior acoustic shadowing less often observed (27% versus
47%, p = 0.040).
Tumor characteristics with impact on the sonomorphology
Overall, we performed 12 group comparisons with re-
spect to the ultrasound features. The groups were de-
fined either by clinical characteristics (e.g. age, breast
density) or by the tumor biology (e.g. histology grade, re-
ceptor status, HER2 status). Depending on the groups ob-
served, the number of significantly different ultrasound
Figure 6 Overview of the results I. Influence of the tumor biology and patient’s characteristics on the sonomorphology. Significance is
indicated in green. P-values greater than p = 0.100 are indicated as “not significant”. (irr. = irregular; n.s. = not significant; TNBC = triple negative
breast cancer; HR = hormone receptors; h = horizontal; v = vertical; i = indifferent; microlob. = microlobulated; PAF = posterior acoustic features).
Wojcinski et al. BMC Women's Health 2013, 13:47 Page 7 of 11
http://www.biomedcentral.com/1472-6874/13/47features varied from one different feature between groups
to five different features, respectively. We found numerous
differences comparing HR positive and hormone receptor
negative tumors (i.e. rate of lobulated or microlobulated
margin, presence of echogenic halo, posterior acoustic fea-
tures and changes in Cooper’s ligaments) and comparing
TNBC and non-TNBC. Furthermore, patient’s age (inde-
pendent from the chosen cut-off) had a considerable ef-
fect on the sonomorphology of tumors. Regarding the
tumor size, T1 tumors frequently exhibited different fea-
tures than larger tumors (i.e. shape, presence of lobulated
margin, rate of angulated or spiculated margin and archi-
tectural distortions) [Figure 6].
Sonographic features that frequently varied between
the groups
We compared 16 ultrasound characteristics between the
groups in different categories. Focusing on the ultra-
sound features, the tumor biology proved a considerableeffect on various elements. Amongst others, the presence
of a lobulated or microlobulated margin and the presence
of an echogenic halo were relevantly influenced by the
tumor biology. Furthermore, the posterior acoustic fea-
tures frequently varied between the investigated groups.
Finally, the frequency of architectural distortions and
changes of the Cooper’s ligaments were frequently dis-
similar between the groups [Figure 6].
Discussion
Is it plausible, that the tumor biology has an impact on
the sonomorphology?
Breast cancer is not merely characterized by features
that can obviously be detected by clinical examination,
medical imaging or visual evaluation of a tumor specimen,
but rather by distinct intrinsic attributes. Essential tumor
characteristics, like histology grade, hormone receptor sta-
tus and HER2 expression, have a biological, proteomic or
genetic background. Therefore, the characterization of
Figure 7 Overview of the results II. Influence of the tumor biology and patient’s characteristics on clinical features of the tumor. Significance is
indicated in green. P-values greater than p = 0.100 are indicated as “not significant”. (n.a. = not applicable; n.s. = not significant; TNBC = triple
negative breast cancer; HR = hormone receptors; d = ductal; l = lobular; o = others).
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scopic to the molecular dimension.
In the first instance, it has to be considered if it is
plausible that differences in the molecular attributes of
breast cancer can have an impact on the sonomorphol-
ogy of the tumor. Ultrasound is principally capable of
visualizing macroscopic qualities of a mass and thus de-
tecting differences in the gross appearance. However,
our results demonstrate that even sub-microscopic fea-
tures of a tumor may modify its appearance in ultra-
sound. Understandably, ultrasound cannot directly
detect intrinsic parameters of the tumor and it cannot
be the aim to predict these parameters by imaging
methods. Nevertheless, the typical ultrasound features of
malignant breast masses may vary in distinct tumor
types. Knowledge about these variations would help the
examiner to avoid the false classification of breast le-
sions. Depending on the chosen groups, we detected a
various number of different ultrasound features.Data from the literature
The common features of malignant breast tumors are
described in specialized books [11]. Furthermore, the
American College of Radiology (ACR) has published refer-
ence guidelines on the categorization of breast tumors ac-
cording to their ultrasound characteristics [14]. However,
breast cancer cannot be regarded as a single disease and
according to histological, immunohistochemical or genetic
features, several subtypes can be distinguished [8-10]. Al-
though there has never been a detailed and systematic ap-
proach before, we found data in the literature that focuses
on certain (sono-) morphologic features of distinct sub-
types and that will be discussed in the following sections.
Histological tumor type
ILC may be occult in both mammography and ultra-
sound, and breast-MRI may have certain advantages in
the detection of this tumor type [18,19]. However, the
sensitivity of ultrasound seems to be higher than
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mann et al. published data on the ultrasound features of
ILC cancer [21]. They found that an irregular shape, indis-
tinct margins and posterior acoustic shadowing were de-
scribed significantly more often in ILC than in other
tumor types (88% versus 67%, p < 0.001; 95% versus 76%,
p = 0.001; 84% versus 58%, p = 0.001, respectively). These
findings partly comply with our own results (85% versus
71%, p = 0.116; 97% versus 94%, p = 0.700; 59% versus
45%, p = 0.164), as we found corresponding tendencies,
but did not reach a level of statistical significance. Never-
theless, we can support the theory that histological differ-
entiation modifies the ultrasonographic appearance of
breast cancer. To our interpretation, the posterior acoustic
features are of special importance in ILC. We found that
posterior acoustic enhancement is observed significantly
less often in ILC (3% versus 16%, p = 0.023) and either
shadowing or mixed features or no features is significantly
more frequently observed. The detectability of ILC is often
impaired in both mammography and ultrasound as this
tumor type has a diffuse and frequently multicentric
growth pattern and does not present as a mass. However,
a slight architectural distortion with a related posterior
acoustic shadowing may be the only hint for this tumor
type in ultrasound [22]. The sonographer should be aware
of the distinct ultrasound features of ILC in order to avoid
false-negative diagnosis. We did not focus on rare histo-
logical types of breast malignancies (e.g. mucinous, me-
dullary, tubular, mixed forms, metastases) as these entities
only represented a small number of cases in our study.
However, we want to emphasize, that these tumors, in
particular, tend to exhibit imaging characteristics that are
unique and that may be different compared to IDC and
ILC. Ultrasound features of these subtypes are described
elsewhere [23-27].
HER2 status
Focusing on the HER2 status, architectural distortions
were observed significantly more often in HER2 positive
tumors than in HER2 negative tumors (91% versus 78%).
Gene amplification and/or protein over-expression of
HER2 results in a more aggressive phenotype with in-
creased cell proliferation, motility and tumor invasiveness,
accelerated angiogenesis, and reduced apoptosis [28,29].
These biological behaviors imply a rapid infiltration and
destruction of the surrounding tissue and, consequently,
influence both the macroscopic growth pattern of the
tumor and the appearance on ultrasound. The resulting
architectural distortions are a reliable predictor for malig-
nancy and occur in the majority of HER2 positive tumors
(91%). Therefore, HER2 positive tumors may be regularly
detected and classified as probably malignant by ultrasound.
In the literature, we found no conclusive data that could
be compared to our results.Hormone receptor status and triple negativity
Apparently, the HR status with the associated biological
background has a strong impact on the expression of
sonographic features. In an earlier analysis of 281
women, Aaltomaa et al. correlated HR status with histo-
logical variables and mitotic indices [30]. The authors
described a relation to nuclear grade, tumor necrosis,
tumor circumscription, inflammatory cell reaction, intra-
ductal growth pattern and tubule formation. The authors
concluded that HR negativity implies an increased prolif-
eration rate and a number of malignant histological fea-
tures in breast lesions. These histological features may
explain the variation in the ultrasound characteristics
between HR positive and HR negative cancers concern-
ing a lobulated or microlobulated margin, an echogenic
halo, the posterior acoustic feature and changes in the
Cooper’s ligaments. Just recently, Aho et al. published
data on 101 breast tumors. The authors concluded, that
posterior acoustic shadowing was more often associated
with ER positive tumors (90.9% versus 9.1%) and PR
positive tumors (72.7% versus 27.3%). This corresponds
well with our results (47% versus 20%), although the dif-
ferences are less accentuated in our case series, which
can be explained, as we analyzed the global HR status
and did not differentiate between ER and PR [31].
Echo pattern
The most frequently observed echo pattern in breast
cancer are hypoechoic tumors (86%). We found no vari-
ables that influence the distribution of echogenicity. Our
results comply with reports in the literature that also
found no difference in the groups with respect to histo-
logical size, grade, axillary metastases, hormone receptor
status and lymphovascular invasion [31,32].
Patient’s age
Virtually independent from the cut-off, stratification by
age revealed that younger patients were more likely to
exhibit round or oval tumors and a lobulated or micro-
lobulated margin. On the other hand, they were less
likely to show an echogenic halo, architectural distor-
tions and disruption of the Cooper’s ligaments. Conse-
quently, the tumors may lose some of the typical criteria
for malignancy in young patients and may be misjudged
as benign lesions if the sonographer is not fully aware of
this behavior. This phenomenon cannot be explained by
the patient’s age alone, but must be considered as a coin-
cidental effect that is mainly triggered by the distinct
tumor biologies that are common in young patients. Re-
cently, Bullier et al. published data on 97 cases of breast
cancer in women under 40 years old [33]. The authors
concluded, that young women have more luminal
B/Her2+ phenotypes and that the appearance of cancers
is correlated with their biological profiles. Consequently,
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not by patient’s age. We support this interpretation as our
results suggest the same interrelation.
Limitations of our study
The main limitation of our study is that there was only
one observer and image analysis was based on a single,
previously acquired still image. Although the observer
was blinded, this circumstance may impair some of the
results. However, for further studies we would propose
to include multiple observers and provide multiple im-
ages of each tumor or even video loops. Furthermore,
the considerable number of groups and observed vari-
ables may boost statistical errors: Following stratifica-
tion, we performed about 310 comparisons and
calculated the statistical significance between the various
groups. However, with an error rate of 5%we could ex-
pect no more than 16 positive results by chance. Finally,
we found 93 differences that were statistically significant.
Therefore, we consider that most of the positive results
reflect objective differences between the groups. Neverthe-
less, it has to be considered that some of the apparent dif-
ferences between groups may be invalid for statistical
reasons.
Conclusions
Precise evaluation of breast masses before further diag-
nostic or therapeutic steps has a crucial impact on the
quality of the treatment and the outcome in the patient.
Lesion assessment by ultrasound is based on the ACR
BI-RADS®-US classification system that provides a sub-
stantial source for the prediction of the malignant or be-
nign aspects of a tumor. Nevertheless, not each breast
cancer follows the rules of typical ultrasound criteria for
malignancy and variations may occur depending on indi-
vidual factors, such as patient’s characteristics and tumor
biology. Usually, round or oval shape is associated with
benign lesions, but may also occur in certain types of
breast cancer. An echogenic halo is an indicator for ma-
lignancy, but it is frequently absent in HR negative tu-
mors. Moreover, posterior acoustic enhancement is
associated with benign lesions, but may also occur in
high-grade tumors, HR negative tumors and young pa-
tients. Finally, architectural distortions are less often
observed in small tumors, young patients and Her2
negative tumors.
Therefore, false classification of breast masses may
arise with all of the known consequences for the patient.
For the advanced sonographer it is essential to be aware
of potential variations in the ultrasound morphology of
breast tumors. This knowledge would enable the exam-
iner to improve the diagnostic accuracy in the evaluation
of breast lesions and finally help to guide the patient in
the proper therapeutic direction.Abbreviations
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